Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 3Neoplasms 2Thoracic Neoplasms 1Squamous Non-small Cell Lung Cancer 1Squamous Non Small Cell Lung Cancer 1Solid Tumors 1Solid Tumor, Adult 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Non-small Cell Lung Cancer Metastatic 1Neoplasm Metastasis 1Lung Diseases 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 19Pemetrexed 10Paclitaxel 7pembrolizumab 5Nivolumab 5Cisplatin 5Gemcitabine 4osimertinib 3entinostat 3camrelizumab 3atezolizumab 3Erlotinib Hydrochloride 3Bronchoscopy 3zipalertinib 2selpercatinib 2pralsetinib 2durvalumab 2apatinib 2Vinorelbine 2Surveys and Questionnaires 2One-Lung Ventilation 2Ipilimumab 2Drug Delivery Systems 2Docetaxel 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2zimberelimab 1toripalimab 1taletrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Diseases × necitumumab × Clear all
NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Withdrawn
Thoracic

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡